Hagens Berman Continues Abiomed Investigation into Possible Securities Law Violations on Behalf of Investors

more+
less-

Hagens Berman, an investor-rights law firm, is continuing to investigate Abiomed Inc. (NASDAQ:ABMD) regarding possible securities law violations following the company’s disclosure of a Department of Justice (DOJ) probe into the marketing and labeling of its flagship product, the Impella 2.5 system.

LOADING PDF: If there are any problems, click here to download the file.

Published In: Securities Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Steve Berman, Hagens Berman | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »